Qingdao Baheal Medical INC. (SHE:301015)

Market Cap	12.18B -5.4%
Revenue (ttm)	7.58B -9.9%
Net Income	527.03M -34.7%
EPS	0.97 -34.5%
Shares Out	525.62M
PE Ratio	23.90
Forward PE	20.15
Dividend	0.76 (3.29%)
Ex-Dividend Date	May 27, 2025

Volume	8,874,087
Average Volume	3,760,260
Open	21.90
Previous Close	23.17
Day's Range	21.82 - 22.99
52-Week Range	17.37 - 32.38
Beta	0.61
RSI	55.19
Earnings Date	Apr 29, 2026

About SHE:301015

Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and the United Kingdom. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; liver disease drugs under the Fuzhenghuayu brand name; and urological drugs under the Betanli, Harle, and Wei Xi Kang brand names. It also provides ophthalmic drugs under the HYCOSAN brand name; tumor and other severe drugs under the Human Albumin ...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2005
• Employees: 3,064
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301015

Financial Performance

In 2024, SHE:301015's revenue was 8.09 billion, a decrease of -1.96% compared to the previous year's 8.26 billion. Earnings were 691.59 million, a decrease of -2.87%.